Antihypertensive drugs and the risk of gastrointestinal bleeding

American Journal of Medicine

Volumn 105, Issue 3, 1998, Pages 230-235

  Suissa, Samy ^a,b   Bourgault, Chantal ^a   Barkun, Alan ^a   Sheehy, Odile ^a   Ernst, Pierre ^a  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CANADA; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK;

EID: 0032168640     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00239-3     Document Type: Article

References (37)

1. 1. Pahor M, Guralnik JM, Furberg CD, et al. Risk of gastrointestinal hemorrhage with calcium channel antagonists in hypertensive persons over 67 years old. Lancet. 1996;347:1061-1065.
2. 2. Wagenknecht LE, Furberg CD, Hammon JW, et al. Surgical bleeding: unexpected effect of calcium antagonist. BMJ. 1995;310: 776-777.
3. 3. Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction study. Thrombolysis in myocardial infarction, phase II, pilot and clinical trial. Circulation. 1991;83:448-459.
4. 4. Kario K, Imiya M, Ohat Y, Shimada K. Gastrointestinal bleeding induced by amlodipine. J Hum Hypertens. 1995;9:206-207.
5. 5. Gordon RD. Calcium channel blockers and gastrointestinal haemorrhage: the balancing act. Lancet. 1996;347:1056.
6. 6. Strand LM, Downey W. Health databases in Saskatchewan. In: Strom BL, ed. Pharmacoepidemiology. New York: John Wiley & Sons; 1994:217-229.
7. 7. Rawson NS, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med. 1995;14:2627-2643.
8. 8. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom BL, ed. Pharmacoepidemiology. New York: John Wiley & Sons; 1994:629-645.
9. 9. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics. 1984;40:63-75.
10. 10. Robins JM, Prentice RL, Blevins D. Designs for synthetic case-control studies in open cohorts. Biometrics. 1989;45:1103-1116.
11. 11. Von Korff M, Wagner EH, Saunders K. A Chronic Disease Score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
12. 12. Garcia Rodriguez LA, Cattaruzi C, Grazia Troncon M, Agostinis L. Risk of hospitalization for upper gastrointestinal bleeding associated with Ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 1998;158:33-39.
13. 13. Rostagno C, Abbate R, Gensini GF, et al. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil. Thrombos Res. 1991;63:457-462.
14. 14. Blache D, Ojeda C. Comparative inhibitory effects of dihydropyridines on platelet aggregation, calcium uptake and cyclic AMP concentration. Pharmacology. 1992;45:250-259.
15. 15. Pietraszek MH, Chabielska E, Buczko W, Effects of verapamil, diltiazem and nifedipine on some parameters of hemostasis in the rat. Thrombos Res. 1988;50:325-328.
16. 16. Ding YA, Han CL, Chou TC, et al. Effects of the calcium antagonist isradipine on 24-hour ambulatory blood pressure, platelet aggregation, and neutrophil oxygen free radicals in hypertension. J Cardiovasc Pharmacol. 1992;19(suppl 3):S32-37.
17. 17. Rostagno C, Prisco D, Paniccia R, et al. Effects of calcium channel blockers on platelet aggregation and thromboxane A2 formation: an in vivo double blind randomized study. Thrombos Res. 1990;59: 531-539.
18. 18. Feinberg WM, Bruck DC. Effect of oral nimodipine on platelet function. Stroke. 1993;24:10-13.
19. 19. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298: 636-642.
20. 20. Kario K, Imiya M, Ohta Y, Shimada K. J Hum Hypertens. 1995;9: 206-207. Letter.
21. 21. Grimm I, Shaheen N. Calcium channel blockers and gastrointestinal hemorrhage: more bad press? Gastroenterology. 1996;111:1391-1393.
22. 22. Grodecki-De Franco PV, Steinbul SR, Taylor PC, et al. Calcium antagonist use and perioperative bleeding complications: an analysis of 5,157 patients. Circulation. 1996;(suppl):I-476.
23. 23. Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. NEJM. 1991;324:1532-1538.
24. 24. Bernard B, Lebrec D, Mathurin P, et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology. 1997;25:63-70.
25. 25. Bernstein DE, Phillips RS. Portal hypertensive gastropathy. Gastrointest Endosc Clin North Am. 1996;6:697-708.
26. 26. Bhandare P, Diniz-D'Souza R, Mainker A, Dhume V. Protective effect of propranolol on ethanol-induced gastric lesions in mice. Eur J Pharmacol. 1990;191:167-172.
27. 27. Rataboli PV, Bhandare PN, D'Souza RS, Dhume VG. Protective effect of propranolol on ethanol-induced gastric lesions in rats: probable mechanism of action. Ind J Physiol Pharmacol. 1992;36: 35-38.
28. 28. Brandsborg O, Brandsbrog M, Christesen NJ. The role of beta-adrenergic receptor in the secretion of gastrin: studies in normal subjects and patients with duodenal ulcers. Eur J Clin Invest. 1976; 6:395-401.
29. 29. Daly MJ. The classification of adrenoceptors and their effects on gastric acid secretion. Scand J Gastroenterol. 1984;89(suppl):3-9.
30. 30. Asnchelewitsch J, Okun K. Adrenegic processes and partial secretion of the stomach. Zeitschrift fur die Gesamte Innere Medizin und ihre Grenzgebiete. 1976;31:277-280.
31. 31. Jick H, Porter J. Drug-induced gastrointestinal bleeding. Report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. Lancet. 1978;2:87-89.
32. 32. Ryan JR, McMahon FG, Akdamar K, et al. Mucosal irritant potential of a potassium-sparing diuretic and of wax-matrix potassium chloride. Clin Pharmacol Therapeut. 1984;35:90-93.
33. 33. Gleerup G, Peterson JR, Mehlsen J, Winther K. Effect of spirapril and hydrochlorothiazide on platelet function and euglobin clot lysis time in patients with mild hypertension. Angiology. 1996;47: 9541-9545.
34. 34. Touyz RM, Schiffrin EL. Role of protein kinase C in the anti-aggregatory effects of endothelin-1 on human platelets. Clin Sci. 1995;88: 277-283.
35. 35. Rendu F, Bachelot C, Molle D, et al. Indapamide inhibits human platelet aggregation in vitro: comparison with hydrochlorothiazide. J Cardiovasc Pharmacol. 1993;22(suppl 6):S57-63.
36. 36. Garcia Rodriguez LA, Walker AM, Perez Gutthann SP. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology. 1992;3:337-342.
37. 37. Guess HA, West R, Strand LM, et al. Fatal upper gastrointestinal hemorrhage or perforation among users and nonusers of anti-inflammatory drugs in Saskatchewan, Canada, 1983. J Clin Epidemiol. 1988;41:35-45.